Discover how the Oxidized Glycerol Triesters (OGT) technology in Aquoral provides dry mouth relief lasting 4 to 6 hours by forming a protective lipid-based barrier that mimics natural saliva.
Understanding the science behind oxidized glycerol triesters technology
Oxidized Glycerol Triesters (OGT) technology represents a significant advancement in xerostomia management, offering a scientifically validated approach to oral hydration that addresses the fundamental pathophysiology of dry mouth conditions. This patented technology, derived from oxygenated corn oil, functions through a unique mechanism that distinguishes it from conventional aqueous formulations. The molecular structure of OGT enables the formation of a durable, protective lipid-based barrier on oral mucous membranes, effectively mimicking the natural lubricating and protective properties of endogenous saliva.
The therapeutic efficacy of OGT technology lies in its ability to create a sustained moisture-retaining layer that reduces transepithelial water loss and provides continuous mucosal protection. Unlike temporary surface moisturizers, the lipid-based composition of OGT adheres to oral tissues through physiochemical interactions, creating a semi-permeable barrier that maintains tissue hydration while allowing normal cellular respiration. This biomimetic approach addresses the complex etiology of xerostomia by not only providing immediate symptomatic relief but also protecting vulnerable oral tissues from the cascade of complications associated with chronic hyposalivation.
The formulation’s neutral pH of approximately 7.0, similar to that of water and natural saliva, ensures compatibility with the oral environment and minimizes the risk of pH-related tissue irritation or dental demineralization. This pH optimization is particularly critical for people with medication-induced xerostomia, who often experience compromised oral mucosal integrity and increased susceptibility to acidic challenges. The non-toxic, gluten-free composition further enhances safety and tolerability across diverse populations, including those with multiple health conditions or dietary restrictions.
How lipid-based formulations outperform water-based dry mouth treatments
The fundamental limitation of aqueous dry mouth treatments stems from their inherent physical properties and transient residence time on oral mucosal surfaces. Water-based formulations typically provide only brief symptomatic relief, as they are rapidly diluted by residual saliva, swallowed, or absorbed into oral tissues within minutes of application. This necessitates frequent reapplication throughout the day, often every 30 to 60 minutes, which significantly impacts consistency of use and quality of life. The repetitive dosing requirement also increases the overall volume of product consumed, potentially leading to gastrointestinal discomfort and interruption of daily activities.
Lipid-based formulations using OGT technology demonstrate superior performance characteristics through extended mucosal residence time and enhanced protective capabilities. The hydrophobic nature of the lipid barrier creates a more stable interface with oral tissues, resisting displacement by normal oral functions such as speaking, swallowing, and tongue movement. Clinical evaluations have documented relief duration of 4 to 6 hours with just two sprays of Aquoral (a standard dose), representing a substantial improvement over aqueous alternatives. This extended efficacy reduces how often you need to apply it, making it more convenient to use consistently.
The biomechanical properties of lipid-based barriers also provide superior protection against mechanical and chemical insults to oral tissues. The cohesive lipid layer acts as a physical shield, reducing friction during chewing and swallowing while protecting vulnerable mucosa from irritants, allergens, and microbial colonization. This protective function is particularly valuable for people experiencing medication-induced xerostomia, where compromised salivary flow diminishes the mouth’s natural defence mechanisms. By restoring this protective barrier function, lipid-based formulations help maintain oral homeostasis and prevent the progressive tissue damage associated with chronic dry mouth conditions.
Clinical evidence supporting extended relief duration and outcomes
Clinical evaluation of Aquoral has generated evidence supporting its efficacy in managing moderate to severe xerostomia across diverse populations. The clinical data demonstrates that 92% of study participants experienced subjective improvement in dry mouth symptoms following treatment with Aquoral, a clinically significant response rate that supports the approach. This response rate is particularly noteworthy given the varied causes of xerostomia among study participants, including medication-induced, disease-related, and multifactorial dry mouth conditions.
Objective functional outcomes further support the benefit observed with Aquoral. Clinical trial data indicates that 92% of participants experienced measurable improvement in chewing ability, addressing a critical functional deficit that significantly impacts nutritional intake and quality of life. Similarly, 65% of participants demonstrated enhanced swallowing capacity, reducing the risk of dysphagia-related complications and making it easier to take oral medicines. These functional improvements extend beyond mere symptom palliation, representing meaningful restoration of essential oral functions that are often severely compromised in xerostomia.
The sustained effect of Aquoral is reflected in satisfaction measures and continued use. Clinical data reveals that 78% of participants expressed a desire to continue using Aquoral following the initial evaluation period, indicating high levels of satisfaction and perceived benefit. This preference for continued use suggests that people experience not only symptomatic relief but also improvements in overall oral comfort and function that meaningfully enhance daily living. The extended relief duration of 4 to 6 hours per application reduces the burden of frequent dosing and lets people keep up normal daily activities without constant attention to dry mouth management.
Comparative clinical surveys have demonstrated that Aquoral outperforms aqueous treatments in both subjective patient-reported outcomes and objective functional assessments. These findings support the advantage of lipid-based OGT technology over conventional water-based approaches for persistent xerostomia.
The role of neutral pH in protecting oral mucosa and preventing dental complications
The maintenance of physiologic pH in oral care products is a critical consideration for preventing damage to dental hard tissues and oral soft tissues. Many oral hygiene products and dry mouth treatments contain acidic components that, with repeated exposure, contribute to dental erosion, enamel demineralization, and mucosal irritation. For people with xerostomia, whose natural buffering capacity is already compromised by reduced salivary flow, exposure to acidic formulations poses a particularly significant risk for accelerated tooth decay, gum disease, and oral mucosal breakdown.
Aquoral’s neutral pH formulation, calibrated to approximately 7.0, provides a dentally safe alternative that supports rather than undermines oral health. This pH optimization ensures that each application does not contribute to the demineralization process or create an acidic microenvironment conducive to cavity-causing bacteria. The neutral pH also minimizes the risk of chemical irritation to compromised oral mucosa, which is especially important for people with Sjögren’s syndrome, radiation-induced xerostomia, or medication-related mucosal sensitivity. By maintaining pH homeostasis, Aquoral lets people manage dry mouth symptoms without incurring additional oral health risks.
The protective effect of neutral pH formulations extends to the preservation of oral microbiome balance and the prevention of opportunistic infections. Chronic xerostomia creates an ecological shift in oral microbial populations, often favouring acid-producing species associated with dental caries and periodontal disease. The use of pH-neutral protective barriers helps maintain a more physiologic oral environment, supporting beneficial organisms and reducing the selective pressure for harmful species. This is particularly relevant for people with weakened immune systems and those taking long-term medicines for chronic conditions.
Clinical evidence demonstrates that the combination of neutral pH and protective lipid barrier technology effectively reduces the incidence of mucosal damage and tooth decay in people with chronic xerostomia. By addressing both the symptomatic and underlying aspects of dry mouth, Aquoral provides oral protection that extends beyond immediate symptom relief to long-term preservation of oral health and function.
Relief for medication-induced dry mouth
Medication-induced xerostomia is one of the most common and challenging forms of dry mouth, affecting people receiving treatment for cardiovascular disease, psychiatric disorders, diabetes, autoimmune conditions, and numerous other chronic illnesses. Anticholinergic, antidepressant, antipsychotic, antihypertensive, antihistamine, and antiparkinson medications are among the many drug classes with well-documented drying effects. Taking several medicines at once, common in older adults, further compounds this issue, with cumulative anticholinergic burden producing severe and persistent dry mouth that significantly impacts quality of life and medication adherence.
Aquoral addresses the needs of people with medication-induced xerostomia by providing extended-duration relief that accommodates the chronic and often irreversible nature of drug-related salivary dysfunction. Aquoral’s OGT technology delivers mucosal protection and hydration that meets the demands of moderate to severe dry mouth. In Canada, Aquoral is available without a prescription, and your doctor, dentist or pharmacist can help you fit it into a plan that addresses both your underlying condition and the drying side effects of your medicines.
Aquoral can help people across many medication classes. People taking opioid pain medicines may find improved oral comfort that makes it easier to maintain nutrition and oral hygiene. People treated with anticholinergic medications for overactive bladder, COPD, or Parkinson’s disease may notice clearer speech and easier swallowing. People receiving chemotherapy or radiation therapy may find relief from treatment-related dryness. For people on PAP therapy for sleep apnea, Aquoral provides nighttime oral lubrication that can improve sleep comfort and device tolerance. By relieving medication-induced dry mouth, Aquoral helps you keep taking the medicines you need while preserving oral health, comfort, and function.
This article is general information and does not replace advice from your health professional. Content adapted for Canada; pending review.